Chill Brands Group PLC (CHBRF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Chill Brands Group PLC (CHBRF) trades at $0.05 with AI Score 38/100 (Grade D). Chill Brands Group PLC is a London-based company specializing in the research, development, manufacturing, and distribution of cannabidiol (CBD) and lifestyle consumer products. Market cap: $24.45M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for CHBRF: CHBRF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CHBRF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CHBRF: 1/1 perspectives are bearish.
How is this calculated? →Chill Brands Group PLC (CHBRF) Healthcare & Pipeline Overview
Chill Brands Group PLC, founded in 2014, specializes in the research, development, manufacturing, and distribution of cannabidiol (CBD) and lifestyle consumer products. Operating under the Chill.com and Zoetic brands across the US, UK, and Europe, the company offers a diverse portfolio including tobacco alternatives and wellness items.
What Is the Investment Thesis for CHBRF?
Chill Brands Group PLC operates within the expanding global market for cannabidiol (CBD) and lifestyle consumer products, leveraging its integrated approach from R&D to distribution under the Chill.com and Zoetic brands. The company's diverse product portfolio, encompassing tobacco alternatives and wellness items, positions it to capitalize on increasing consumer interest in natural health solutions and alternative consumption methods. Key value drivers include potential market penetration in the US, UK, and European CBD markets, driven by product innovation and brand recognition. However, the company faces significant operational challenges, evidenced by a profit margin of -778.6% and a gross margin of -108.8%, indicating substantial losses relative to revenue and cost of goods sold. Its small market capitalization of $24.45M and status on the OTC Other tier suggest lower liquidity and heightened investment risk. Future growth catalysts depend heavily on favorable regulatory developments in the CBD industry across its operating regions and the company's ability to achieve sustainable revenue generation and improve profitability metrics. Investors may want to evaluate the high-risk, high-reward nature associated with early-stage companies in a nascent, evolving industry, particularly those with negative profitability and OTC market listing.
Based on FMP financials and quantitative analysis
CHBRF Key Highlights
- Market Capitalization: $0.02 billion, indicating a micro-cap company with limited market liquidity.
- Profit Margin: -778.6%, reflecting substantial net losses relative to sales, highlighting significant operational challenges.
- Gross Margin: -108.8%, suggesting that the cost of goods sold exceeds revenue, indicating fundamental issues in product pricing or production efficiency.
- Beta: 0.80, indicating lower volatility compared to the broader market, though this can be influenced by low trading volume in OTC markets.
- Employee Count: 7 employees, signifying a lean operational structure for a company with international aspirations.
Who Are CHBRF's Competitors?
CHBRF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CHBRF's Key Strengths?
- Comprehensive R&D to distribution model for consumer products.
- Diverse product portfolio including CBD wellness items and tobacco alternatives.
- Established brands: Chill.com and Zoetic.
- Geographic presence in the US, UK, and wider Europe.
What Are CHBRF's Weaknesses?
- Significant negative profitability (Profit Margin: -778.6%, Gross Margin: -108.8%).
- Small market capitalization ($0.02B) and limited employee base (7 employees).
- Operating in the OTC Other tier, implying potentially lower liquidity and reporting standards.
- Unknown disclosure status on the OTC market.
What Could Drive CHBRF Stock Higher?
- Potential favorable regulatory changes in the United States or European markets regarding CBD product sales and marketing, which could expand market access.
- Introduction of new, innovative CBD-infused products or expansion into new wellness categories that gain significant consumer traction.
- Efforts to secure new distribution partnerships or expand existing retail footprints in key geographic markets (US, UK, Europe).
- Strategic initiatives aimed at improving operational efficiency and reducing the substantial negative gross and profit margins.
- Any public disclosures or financial reporting that clarifies the company's operational performance and financial health, addressing the "Unknown" disclosure status.
What Are the Key Risks for CHBRF?
- Financial-distress signal — its Altman Z-Score of -21.56 sits in the distress zone (elevated bankruptcy risk).
- Significant negative profitability and gross margins (-778.6% and -108.8% respectively), indicating fundamental challenges in achieving financial viability.
- High regulatory uncertainty and potential for adverse policy changes in the evolving global CBD market, impacting product legality and market access.
- Intense competition from well-capitalized companies and numerous smaller players in the fragmented CBD and wellness product sectors.
- Risks associated with trading on the OTC Other tier, including low liquidity, wide bid-ask spreads, and limited public disclosure, making investment highly speculative.
- Challenges in scaling operations and achieving wider market penetration with a small employee base (7 employees) and limited financial resources.
What Are the Growth Opportunities for CHBRF?
- Expansion in the Global CBD Market: The global cannabidiol (CBD) market is projected to continue its robust growth trajectory, driven by increasing consumer acceptance and expanding legal frameworks. Chill Brands Group PLC, with its established brands Chill.com and Zoetic, is positioned to capitalize on this trend by broadening its product distribution channels and market reach across the United States, United Kingdom, and Europe. As regulatory clarity improves and public perception shifts positively, the addressable market for CBD-infused wellness and lifestyle products is expected to expand significantly, offering a substantial growth runway for companies capable of scaling operations and maintaining product quality.
- Diversification of Product Portfolio: Chill Brands Group PLC's current product range includes tobacco alternatives, oral tinctures, soft-gel capsules, massage oils, and topical cosmetics. Further diversification into new product categories, such as functional beverages, pet CBD products, or specialized therapeutic applications, could unlock new revenue streams. The wellness market is dynamic, and consumers are increasingly seeking innovative solutions. By leveraging its R&D capabilities, the company can introduce novel CBD formulations and delivery methods that cater to niche markets or emerging health trends, thereby expanding its total addressable market and reducing reliance on existing product lines.
- Strategic Geographic Market Penetration: While Chill Brands Group PLC currently operates in the US, UK, and wider Europe, there remains significant potential for deeper penetration within these regions and expansion into new international markets. Focusing on strengthening distribution networks, forming strategic partnerships with local retailers, and tailoring product offerings to specific cultural preferences in under-penetrated European countries could drive substantial growth. Each new market offers a distinct regulatory environment and consumer base, requiring targeted strategies to establish brand presence and capture market share effectively.
- Brand Building and Direct-to-Consumer (DTC) Channels: Investing in robust brand building initiatives for Chill.com and Zoetic, coupled with enhancing direct-to-consumer (DTC) e-commerce platforms, presents a significant growth opportunity. A strong brand identity fosters consumer trust and loyalty, which is crucial in a crowded market. DTC channels allow for higher profit margins by cutting out intermediaries, provide direct access to consumer data for product development, and enable agile marketing campaigns. Expanding digital marketing efforts and optimizing the online shopping experience can significantly increase customer acquisition and retention, driving organic sales growth.
- Leveraging Regulatory Evolution: The regulatory landscape for CBD products is continually evolving, with potential for both challenges and opportunities. As more countries and regions establish clear guidelines for CBD production, marketing, and sales, Chill Brands Group PLC can leverage these developments to expand its offerings and market access. Compliance with new regulations could open doors to mainstream retail channels and broader consumer acceptance. Proactive engagement with regulatory bodies and adherence to stringent quality standards could position the company as a trusted leader, gaining a competitive edge as the industry matures and consolidates.
What Opportunities Does CHBRF Have?
- Expanding global market for CBD products driven by increasing consumer acceptance.
- Potential for new product development and diversification within the wellness sector.
- Leveraging evolving regulatory frameworks to expand market access and product offerings.
- Strengthening direct-to-consumer channels and brand building.
What Threats Does CHBRF Face?
- Intense competition from established and emerging players in the CBD and wellness markets.
- Unfavorable or restrictive regulatory changes in key operating regions.
- Challenges in achieving wider market penetration and sustainable profitability.
- Reputational risks associated with the nascent and sometimes controversial CBD industry.
What Are CHBRF's Competitive Advantages?
- Brand Recognition: Established brands like Chill.com and Zoetic in the nascent CBD market can foster consumer trust and loyalty.
- Diverse Product Portfolio: A broad range of products from tobacco alternatives to wellness and cosmetics caters to varied consumer needs, potentially reducing reliance on a single product line.
- Integrated Operations: Managing R&D, manufacturing, and distribution internally allows for greater quality control, supply chain efficiency, and potentially faster time-to-market.
- Geographic Reach: Presence in the US, UK, and wider Europe provides a multi-market approach, diversifying revenue streams and mitigating regional regulatory risks.
What Does CHBRF Do?
Chill Brands Group PLC, a London-based entity established in 2014, operates as a comprehensive consumer products company, overseeing the entire process from initial research and development to manufacturing and distribution. The firm's core focus lies in cannabidiol (CBD) consumer items, complemented by a broader range of lifestyle goods, marketed under its proprietary brands, Chill.com and Zoetic. The company's operational footprint extends across key international markets, including the United States, the United Kingdom, and the wider European continent, reflecting its ambition for broad market penetration within the burgeoning CBD and wellness sectors. The product portfolio is diverse, addressing various consumer needs and preferences. It includes innovative tobacco alternatives, such as CBD-infused smokes and chewable pouches, designed to cater to individuals seeking alternatives to traditional tobacco products. Beyond this, Chill Brands Group PLC offers an array of wellness and personal care items. This segment encompasses oral tinctures, which provide a discreet method for CBD consumption; soft-gel capsules, offering precise dosing and convenience; massage oils, formulated for topical application and localized relief; and various topical cosmetic solutions, integrating CBD into daily skincare routines. The company's evolution saw a significant rebranding in August 2021, when it formally adopted the name Chill Brands Group PLC, transitioning from its previous identity as Zoetic International Plc. This strategic shift underscored its sharpened focus on the "Chill Brands" identity and its expanding product lines. With its vertically integrated approach and diverse product offerings, Chill Brands Group PLC aims to capture market share in the rapidly evolving global CBD and lifestyle product industries.
What Products and Services Does CHBRF Offer?
- Researches and develops cannabidiol (CBD) and lifestyle consumer products.
- Manufactures a range of CBD-infused items and other consumer goods.
- Distributes products across the United States, United Kingdom, and Europe.
- Operates under the proprietary brands Chill.com and Zoetic.
- Offers tobacco alternatives, including CBD smokes and chewable pouches.
- Provides wellness and personal care products like oral tinctures and soft-gel capsules.
- Develops topical solutions such as massage oils and cosmetic items.
- Manages the entire product lifecycle from concept to market.
How Does CHBRF Make Money?
- Generates revenue through the sale of CBD-infused consumer products and lifestyle goods.
- Utilizes a comprehensive, vertically integrated approach covering R&D, manufacturing, and distribution.
- Markets products under its own brands, Chill.com and Zoetic, targeting a diverse consumer base.
- Focuses on both direct-to-consumer sales and wholesale distribution channels across multiple geographies.
- Aims to capitalize on the growing demand for natural wellness products and tobacco alternatives.
What Industry Does CHBRF Operate In?
Chill Brands Group PLC operates within the Drug Manufacturers - Specialty & Generic industry, specifically focusing on the burgeoning cannabidiol (CBD) segment. This industry is characterized by rapid innovation, evolving regulatory landscapes, and increasing consumer demand for natural wellness and alternative products. The global CBD market is experiencing significant growth, driven by increasing awareness of CBD's potential therapeutic benefits and the gradual legalization of cannabis-derived products in various jurisdictions. Chill Brands Group PLC positions itself by offering a diverse range of CBD consumer items and lifestyle goods, including tobacco alternatives and personal care products, under its Chill.com and Zoetic brands. The competitive landscape is fragmented, comprising numerous small-to-medium enterprises alongside larger pharmaceutical and consumer goods companies entering the space. Chill Brands Group PLC aims to differentiate through its comprehensive R&D to distribution model and a broad product portfolio spanning multiple consumption methods and applications, targeting consumers in the United States, United Kingdom, and Europe.
Who Are CHBRF's Key Customers?
- Consumers seeking CBD-infused wellness products for general well-being.
- Individuals looking for tobacco alternatives, such as CBD smokes and chewable pouches.
- Customers interested in personal care and cosmetic items with CBD benefits.
- Retailers and distributors in the United States, United Kingdom, and Europe.
- Health-conscious individuals exploring natural supplements and lifestyle goods.
How Chill Brands Group PLC Is Valued
Chill Brands Group PLC carries a market capitalization of $24.45M, placing it in the micro-cap category. Relative to its peer group, CHBRF's quantitative score of 38/100 is below the peer average of 66/100.
Company Profile
Chill Brands Group PLC operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in London, GB. The company is led by CEO Graham John William Duncan. CHBRF has traded publicly since 2015.
ROE 234%Key Financial Metrics
Return on equity for Chill Brands Group PLC stands at 233.8%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.87 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 4/9Financial Health
Chill Brands Group PLC's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -21.56 places it in the distress zone, a signal of elevated financial risk.
CHBRF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Comprehensive R&D to distribution model for consumer products.
- Diverse product portfolio including CBD wellness items and tobacco alternatives.
- Established brands: Chill.com and Zoetic.
- Geographic presence in the US, UK, and wider Europe.
Bear Case
- Significant negative profitability (Profit Margin: -778.6%, Gross Margin: -108.8%).
- Small market capitalization ($0.02B) and limited employee base (7 employees).
- Operating in the OTC Other tier, implying potentially lower liquidity and reporting standards.
- Unknown disclosure status on the OTC market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
CHBRF Latest News
No recent news available for CHBRF.
CHBRF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CHBRF.
Price Targets
Wall Street price target analysis for CHBRF.
CHBRF MoonshotScore
What does this score mean?
The MoonshotScore rates CHBRF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Graham John William Duncan
CEO
Graham John William Duncan serves as the CEO of Chill Brands Group PLC, overseeing the strategic direction and operational management of the London-based consumer products company. His leadership is crucial in navigating the complexities of the cannabidiol (CBD) and lifestyle goods market. While specific details regarding his prior career history, educational background, or previous roles are not provided in the source data, his current position involves managing a lean team of 7 employees, indicating a hands-on approach to the company's development and market execution.
Track Record: Under Graham John William Duncan's leadership, Chill Brands Group PLC has continued its focus on the research, development, manufacturing, and distribution of CBD and lifestyle consumer products. A notable milestone during his tenure was the formal adoption of the Chill Brands Group PLC name in August 2021, signifying a strategic rebranding from its previous identity, Zoetic International Plc. This change aimed to consolidate the company's market presence under a unified brand strategy, particularly for its Chill.com and Zoetic product lines.
CHBRF OTC Market Information
Chill Brands Group PLC trades on the OTC Other tier, which is the lowest and most speculative tier of the OTC Markets Group's three marketplaces (OTCQX, OTCQB, and OTC Pink). Unlike companies listed on major exchanges like NYSE or NASDAQ, which must meet stringent financial and governance standards, OTC Other companies have minimal disclosure requirements. This tier is typically for companies that are not willing or able to provide information to the public, or those in default. It implies a higher level of risk for investors due to the lack of transparent financial reporting and regulatory oversight compared to higher tiers or national exchanges.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public information and unknown disclosure status, hindering informed investment decisions.
- Potentially low trading volume and wide bid-ask spreads, leading to poor liquidity and price volatility.
- Absence of stringent regulatory oversight and financial reporting requirements compared to major exchanges.
- Increased susceptibility to fraud or manipulation due to less transparency.
- Difficulty in obtaining reliable valuation metrics due to limited financial data.
- Verify any available financial statements directly from the company or OTC Markets if possible, despite "Unknown" status.
- Research any news or press releases issued by the company, even if not formally filed.
- Assess the company's business model and competitive landscape independently.
- Evaluate the regulatory environment for CBD products in its operating regions.
- Understand the risks associated with the OTC Other tier, including potential for illiquidity.
- Scrutinize management's track record and any public statements.
- Consider the company's ability to generate revenue and achieve profitability given negative margins.
- Formal incorporation in London, GB, indicating a registered business entity.
- Established founding year (2014) and a history of operation, albeit with a name change.
- Identified CEO (Graham John William Duncan) and employee count (7).
- Specific product lines (CBD items, tobacco alternatives, wellness) and brands (Chill.com, Zoetic).
- Stated geographic operations in the US, UK, and Europe.
Chill Brands Group PLC Healthcare Stock: Key Questions Answered
What does Chill Brands Group PLC do, and what products does it offer?
Chill Brands Group PLC, founded in 2014 and based in London, specializes in the comprehensive lifecycle of consumer products, from research and development through manufacturing and distribution. The company's primary focus is on cannabidiol (CBD) consumer items, alongside a broader array of lifestyle goods, marketed under its key brands, Chill.com and Zoetic. Its product portfolio is diverse, encompassing tobacco alternatives such as CBD-infused smokes and chewable pouches, which cater to a growing demand for non-nicotine options. Additionally, the company offers various wellness and personal care items, including oral tinctures and soft-gel capsules for internal consumption, as well as topical solutions like massage oils and cosmetic products for external application. These offerings are distributed across the United States, the United Kingdom, and the wider European continent, aiming to tap into the expanding global wellness and CBD markets.
What are the main risks for CHBRF given its market and operational structure?
Chill Brands Group PLC faces several significant risks stemming from its operational structure and market positioning. Financially, the company exhibits substantial negative profitability, with a profit margin of -778.6% and a gross margin of -108.8%, indicating that its current operations are not generating sufficient revenue to cover costs, let alone yield profit. This raises concerns about long-term financial viability. Furthermore, its listing on the OTC Other tier, coupled with an "Unknown" disclosure status, presents considerable risks related to transparency, liquidity, and regulatory oversight. Investors may struggle to access reliable financial information, and the shares could experience low trading volumes and wide bid-ask spreads, making them difficult to trade. The nascent and evolving regulatory landscape of the global CBD market also poses a continuous threat, as changes in legislation could significantly impact product legality, manufacturing, and distribution capabilities across its key markets in the US, UK, and Europe.
What is Chill Brands Group PLC's strategy for growth in the CBD market?
Chill Brands Group PLC's growth strategy in the CBD market appears centered on leveraging its integrated R&D, manufacturing, and distribution capabilities to expand its product offerings and geographic reach. The company aims to capitalize on the increasing consumer acceptance and market expansion of CBD products by continually diversifying its portfolio beyond existing tobacco alternatives and wellness items. This includes exploring new product categories or enhancing current lines to meet evolving consumer demands in the US, UK, and European markets. A key component of its strategy involves strengthening its brand presence through Chill.com and Zoetic, potentially through enhanced direct-to-consumer channels and strategic partnerships to improve market penetration. Furthermore, the company's ability to adapt to and navigate the complex and evolving regulatory environment for CBD will be critical, as favorable regulatory developments could unlock significant growth opportunities and broader market access.
What are the key factors to evaluate for CHBRF?
Chill Brands Group PLC (CHBRF) holds an AI score of 38/100 (low). Not financial advice.
How frequently does CHBRF data refresh on this page?
CHBRF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CHBRF's recent stock price performance?
Chill Brands Group PLC (CHBRF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive R&D to distribution model for consumer products. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CHBRF overvalued or undervalued right now?
Valuing Chill Brands Group PLC (CHBRF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CHBRF?
Before investing in Chill Brands Group PLC (CHBRF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- No FMP peer tickers were provided in the source data, so a placeholder for competitors was used.
- CEO's exact title and tenure years were not explicitly provided and were inferred or left as null.
- The 'Unknown' disclosure status for OTC markets limits the depth of financial analysis.